Otros idiomas Syndax Pharmaceuticals, Inc.

Acciones

SNDX

US87164F1057

Tiempo real estimado Cboe BZX Otros sitios de cotización 18:30:56 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
21,75 ^USD	-1,00 %		+5,86 %	+0,76 %

08/04	Syndax Pharmaceuticals, Inc. presenta datos pediátricos positivos del ensayo pivotal AUGMENT-101 de revumenib en leucemia aguda KMT2Ar en recaída/refractaria en la sesión plenaria de la ASPHO	CI
28/03	Syndax Pharmaceuticals, Inc. Anuncia la finalización de la inscripción en la cohorte del ensayo pivotal AUGMENT-101 de pacientes con leucemia mieloide aguda mNPM1 en recaída/refractaria	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024	01/05
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum	10/04
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	09/04
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	08/04
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05/04
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	28/03
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed, Refractory KMT2Ar Acute Leukemia	27/03
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment	26/03
Syndax Says Revumenib NDA Granted FDA Priority Review	26/03
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia	26/03
Sector Update: Health Care Stocks Rise Monday Afternoon	18/03
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer	18/03
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer	18/03
Syndax Pharmaceuticals, Inc. Announces Executive Changes	18/03
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	01/03
Syndax: Q4 Earnings Snapshot	27/02
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Syndax Announces Participation at Two Upcoming Investor Conferences	26/02
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024	20/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Syndax Pharmaceuticals, Inc.

Acciones

SNDX

US87164F1057

Otros idiomas

Filtros